This opening segment introduces a discussion on ciltacabtagene autoleucel (cilta-cel) in multiple myeloma and frames the questions the program sets out to answer: how chimeric antigen receptor (CAR) T-cell therapy should be sequenced among the available options, and how care can be coordinated across a network spread between referring practices and treating centers.
The faculty discuss how to individualize the choice between chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies in relapsed multiple myeloma.
Referral barriers can limit access to chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
Doris Hansen, MD, and Prerna Mewawalla, MD, discuss ciltacabtagene autoleucel manufacturing, disease debulking, and bridging therapy before CAR T-cell infusion in patients with multiple myeloma.
Effective community referral pathways can improve access to chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
Timing referral for chimeric antigen receptor (CAR) T-cell therapy is critical when patients with multiple myeloma experience relapse or progressive disease.
Day 28 after ciltacabtagene autoleucel (cilta-cel) infusion marks an important transition for patients with multiple myeloma from center-led care to shared care with the community oncology team.
Doris Hansen, MD, and Prerna Mewawalla, MD, discuss long-term monitoring, infection prophylaxis, and vaccination after ciltacabtagene autoleucel (cilta-cel) therapy for patients with multiple myeloma.
Surbhi Sidana, MD, asks about 2 less common but important delayed toxicities: delayed neurotoxicity and immune effector cell enterocolitis.
Surbhi Sidana, MD, presents 2 practical scenarios: a patient 6 to 7 weeks post-infusion who develops a fever at a local emergency department 4 hours from the treating center, and a patient around 7 to 8 weeks post-infusion who develops facial droop, drooling, and behavioral changes noticed by a spouse.
Closing the program, Surbhi Sidana, MD, asks each panelist what has changed most in her practice this year.
